Rockefeller Capital Management’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.29M | Hold |
137,838
| – | – | ﹤0.01% | 1249 |
|
|
2025
Q1 | $980K | Hold |
137,838
| – | – | ﹤0.01% | 1268 |
|
|
2024
Q4 | $1.61M | Buy |
137,838
+61,800
| +81% | +$721K | ﹤0.01% | 1094 |
|
|
2024
Q3 | $1.56M | Sell |
76,038
-24,876
| -25% | -$511K | ﹤0.01% | 1084 |
|
|
2024
Q2 | $2.26M | Buy |
100,914
+24,569
| +32% | +$550K | 0.01% | 934 |
|
|
2024
Q1 | $2.1M | Buy |
76,345
+19,866
| +35% | +$547K | 0.01% | 992 |
|
|
2023
Q4 | $1.72M | Buy |
56,479
+9,968
| +21% | +$304K | 0.01% | 965 |
|
|
2023
Q3 | $1.47M | Buy |
46,511
+9,658
| +26% | +$305K | 0.01% | 956 |
|
|
2023
Q2 | $1.5M | Buy |
36,853
+4,704
| +15% | +$192K | 0.01% | 945 |
|
|
2023
Q1 | $1.2M | Buy |
32,149
+8,788
| +38% | +$327K | 0.01% | 998 |
|
|
2022
Q4 | $815K | Sell |
23,361
-7,129
| -23% | -$249K | ﹤0.01% | 1084 |
|
|
2022
Q3 | $1.71M | Buy |
30,490
+7,958
| +35% | +$445K | 0.01% | 815 |
|
|
2022
Q2 | $1.17M | Buy |
22,532
+642
| +3% | +$33.2K | 0.01% | 947 |
|
|
2022
Q1 | $1.59M | Buy |
21,890
+6,814
| +45% | +$495K | 0.01% | 883 |
|
|
2021
Q4 | $1.78M | Buy |
15,076
+11,669
| +343% | +$1.38M | 0.01% | 844 |
|
|
2021
Q3 | $457K | Buy |
3,407
+2,727
| +401% | +$366K | ﹤0.01% | 1295 |
|
|
2021
Q2 | $109K | Buy |
680
+54
| +9% | +$8.66K | ﹤0.01% | 1767 |
|
|
2021
Q1 | $50K | Buy |
626
+253
| +68% | +$20.2K | ﹤0.01% | 1891 |
|
|
2020
Q4 | $20K | Buy |
373
+48
| +15% | +$2.57K | ﹤0.01% | 2015 |
|
|
2020
Q3 | $6K | Buy |
+325
| New | +$6K | ﹤0.01% | 2163 |
|
|
2020
Q1 | – | Sell |
-7
| Closed | – | – | 2449 |
|
|
2019
Q4 | $0 | Buy |
+7
| New | – | ﹤0.01% | 2161 |
|